PPBT Purple Biotech Ltd. Stock Quote

PPBT [NASD]

Index	-	P/E	-	EPS (ttm)	-0.77	Insider Own	-	Shs Outstand	18.04M	Perf Week	-0.87%
Market Cap	40.97M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	18.04M	Perf Month	-9.56%
Income	-	PEG	-	EPS next Q	-	Inst Own	11.23%	Short Float	4.67%	Perf Quarter	-18.93%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	19.78	Perf Half Y	-14.66%
Book/sh	3.94	P/B	0.58	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-53.58%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	2.10 - 5.18	Perf YTD	-41.65%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-56.95%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	6.19%	ATR	0.13
Employees	19	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	36.93	Volatility	4.37% 5.11%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	338.01	Prev Close	2.27
Shortable	Yes	LT Debt/Eq	-	Earnings	Aug 04 BMO	Payout	-	Avg Volume	42.62K	Price	2.23
Recom	-	SMA20	-10.03%	SMA50	-8.36%	SMA200	-27.70%	Volume	2,229,469	Change	-1.76%

Aug-04-22 07:30AM	Purple Biotech Reports Second Quarter 2022 Financial Results GlobeNewswire
Jul-14-22 07:30AM	Purple Biotech Announces Executive Leadership Changes GlobeNewswire
May-27-22 07:15AM	Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile GlobeNewswire -6.21%
May-18-22 08:18AM	Purple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients GlobeNewswire +7.02%
May-12-22 08:13AM	Purple Biotech Reports First Quarter 2022 Financial Results GlobeNewswire -6.80%
Apr-11-22 07:37AM	Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting GlobeNewswire -29.97%
Feb-24-22 12:12AM	Could The Solid State plc (LON:SOLI) Ownership Structure Tell Us Something Useful? Simply Wall St.
Feb-09-22 07:00AM	Purple Biotech Reports Second Half and Full-Year 2021 Financial Results GlobeNewswire
Feb-04-22 07:35AM	Purple Biotech Issues Letter to Shareholders GlobeNewswire +6.12%
Jan-06-22 07:30AM	Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors GlobeNewswire
07:24AM	Is Solid State plc's(LON:SOLI) Recent Stock Performance Tethered To Its Strong Fundamentals? Simply Wall St.
Dec-09-21 07:30AM	Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer GlobeNewswire
03:30AM	Is Now An Opportune Moment To Examine Solid State plc (LON:SOLI)? Simply Wall St.
Dec-06-21 07:30AM	Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program GlobeNewswire +6.40%
Nov-03-21 07:30AM	Purple Biotech to Present at the Jefferies London Healthcare Conference GlobeNewswire
Oct-26-21 08:27AM	Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219 GlobeNewswire
Oct-22-21 06:00AM	Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance GlobeNewswire
Sep-24-21 07:38AM	We Think Solid State (LON:SOLI) Can Stay On Top Of Its Debt Simply Wall St.
Sep-13-21 07:00AM	Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update GlobeNewswire
Aug-05-21 08:30AM	Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results GlobeNewswire
Jun-04-21 08:00AM	Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting GlobeNewswire -11.76%
May-26-21 07:38AM	Purple Biotech to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-20-21 07:00AM	Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting GlobeNewswire +8.21%
May-19-21 07:00AM	Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors GlobeNewswire
Apr-23-21 08:00AM	Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients GlobeNewswire
Apr-13-21 08:17AM	Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting GlobeNewswire
Mar-19-21 08:00AM	Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers GlobeNewswire
Mar-11-21 08:02AM	Purple Biotech to Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting GlobeNewswire
Mar-03-21 07:00AM	Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors GlobeNewswire
Mar-02-21 07:00AM	Purple Biotech Provides Corporate Update and Reports Second Half and Full Year 2020 Financial Results GlobeNewswire -6.32%
Jan-18-21 07:41AM	Purple Biotech to Present at the B. Riley Oncology Investor Conference GlobeNewswire
Jan-04-21 09:40AM	Purple Biotech to Ring the Nasdaq Stock Market Opening Bell GlobeNewswire +6.56%

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience